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ABSTRACT The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that in association with 
Raptor, mLST8, PRAS40 and Deptor forms a complex (mTORC1) playing the key role in the regulation of protein 
biosynthesis, transcription, cellular metabolism, apoptosis and autophagy; mainly via direct phosphorylation of 
S6 kinases. mTORC1 is activated by growth factors and amino acids via the activation of Rheb GTPase. In the 
current study, we demonstrate for the first time that the over-expression of Rabin8, which functions as a gua-
nine nucleotide exchange factor for Rab8 GTPase, suppresses phosphorylation of Ser235/Ser236 in ribosomal 
protein S6. Downregulation of Rabin8 using small interfering RNA (siRNA) increases the phosphorylation of 
Ser235/Ser236 in ribosomal protein S6. Furthermore, Rabin8 can be immunoprecipitated with Rheb GTPase. 
These results suggest the existence of a novel mechanism of mTORС1 regulation and its downstream proc-
esses. Since Rabin8 is a known regulator of ciliogenesis, a potential link can exist between regulation of Rheb/
mTORC1 and ciliogenesis.
KEYWORDS complex mTORC1; Rheb; Rabin8; small ribosomal unit protein S6.
ABBREVIATIONS DMEM – Dulbecco’s Modified Eagle’s Medium; FBS – fetal bovine serum; GAP protein – GT-
Pase-activating protein; mTOR – mammalian target of Rapamycin; Rheb – Ras homologue enriched in brain; 
siRNA – small interfering RNA; TBST – Tris-Buffered Saline and Tween 20.
INTRODUCTION
Highly conserved serine/threonine protein kinase 
mTOR (mammalian target of rapamycin) belongs to 
the family of phosphatidyl inositol 3’ kinase-related ki-
nases (PIKK) and is the key enzyme of the mTOR-sig-
naling pathway controlling the accumulation of the cell 
mass in many eukaryotes. mTOR as a catalytic subunit 
is a component of two hetero-olygomeric complexes, 
mTORC1 and mTORC2, that have different functions. 
mTORC1 is a functional dimer containing two subu-
nits of each one of the following proteins: mTOR, Rap-
tor (regulatory associated protein of mTOR), mLST8 
(mammalian lethal with sec-13), PRAS40 (proline-rich 
AKT substrate 40 kDa), and Deptor (DEP-domain-
containing mTOR-interacting protein) [1, 2]. mTORC1 
phosphorylates a wide range of effectors regulating 
the processes of protein synthesis, cell proliferation, 
apoptosis, and autophagy in response to external sig-
nals [3, 4]. mTORC1 regulates translation through the 
direct phosphorylation of 4E-BP (translation initia-
tion factor 4E binding protein), which binds and in-
hibits the initiation factor 4E and phosphorylation of 
S6K1 and S6K2 [5]. These kinases activate translation 
by phosphorylating protein S6, as well as a number of 
other proteins (SKAR, PDCD4, eEF-2K, eIF4B). The 
level of protein S6 phosphorylation using phospho-
specific antibodies against Ser235/Ser236 is used to 
assess the kinase activity of mTORC1 [6].
The activity of mTORC1 is regulated by a number 
of various stimuli, such as growth factors, amino acids, 
glucose, and oxygen. Two key mechanisms are used in 
this regulation: a targeted modification of the compo-
nents of this complex or regulation of Rheb GTPase, 
which directly interacts with mTORC1 and activates 
it when it is bound to GTP. The major Rheb GTPase 
regulator is a heterodimeric complex consisting of two 
tumor growth suppressor proteins: tuberin, containing 
conservative GAP domain, and hamartin, which stim-
ulates the transition of Rheb GTPase from an active 
GTP-bound form into an inactive GDP-bound form. In-72 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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activation of these proteins leads to the constitutive ac-
tivation of Rheb GTPase, which activates mTORC1. As 
a result, the protein synthesizing activity is increased, 
and uncontrolled cell proliferation is observed [7].
It has also been demonstrated that tuberin and 
hamartin have an effect on the formation of primary 
cilia [8]. Interaction of Rab8 GTPase and guanine nu-
cleotide exchange factor Rabin8 [9] activates Rab8 and 
promotes GDP release and GTP binding [10], which is 
involved in regulation of primary cilia formation.
Based on that, it was hypothesized that Rabin8 reg-
ulates Rheb GTPase, the major regulator of mTORC1. 
In the present study we showed that Rabin8 overex-
pression resulted in a decrease of mTORС1 activity, 
whereas downregulation of both Rabin8 and tuberin 
using siRNAs resulted in the activation of mTORC1. 
We also showed that Rabin8 protein could be co-im-
munoprecipitated with Rheb GTPase. Based on these 
data, we concluded that Rabin8 protein acts as a nega-
tive regulator of mTORC1 through binding to Rheb 
GTPase.
EXPERIMENTAL
Reagents and specimens
HEK293 (human embryonic kidney) cells (АТСС, Unit-
ed States) were grown in DMEM with or without 10% 
fetal bovine serum (FBS) (Gibco, United States) added. 
Antibodies against Rabin8 protein (Proteintech, United 
States), tuberin (Abcam, United States), Myc, β-actin 
and mTOR, phosphospecific antibodies against Ser235/
Ser236 in ribosomal protein S6 (Cell Signalling, Unit-
ed States), and rabbit IgG (Santa Cruz Biotechnology, 
United States) were used.
Transfection
Fugene 6 (Roche, United States) was used for the 
transfection of HEK293 cells with plasmid constructs; 
for the transfection with various siRNA, Trans-IT 
TKO reagent (Mirus, United States) was used accord-
ing to the manufacturer’s protocol. HEK293 cells were 
transfected with pcDNA3.1 control vector, vector ex-
pressing Rabin8, pCMVTag3A control vector, or vec-
tor expressing Myc-Rheb fusion protein separately or 
together. Twenty-four hours after the transfection, 
the cells were washed twice and the medium, either 
with or without growth factors, was added. Twenty-
four hours after the medium was replaced, the activity 
of mTORC1 was analyzed based on the phosphoryla- analyzed based on the phosphoryla-  based on the phosphoryla-
tion of ribosomal protein S6 using phosphospecific an-
tibodies against Ser235/Ser236 in protein S6. HEK293 
cells were also transfected with the control, Rabin8 or 
tuberin siRNAs (Dharmacon, United States). Twenty-
four hours after the transfection, the cells were washed 
twice and the medium, either with or without growth 
factors, was added.
Co-immunoprecipitation
Cells were collected in lysis buffer (Cell Signaling, Unit-
ed States) and cell extracts were incubated with anti-
bodies against Rabin8 or Myc for 12 h at 4°С. The re-
sulting complexes were precipitated by incubation with 
protein-A-agarose for 1 hr at 4°С, followed by centrifu-
gation. The proteins were eluted by adding a Laemmli 
buffer, loaded onto denaturing gradient 4–20% poly-
acrylamide gel, and transferred onto polyvinyl mem-
branes (Immobilon-P, Millipore, United States) after 
the electrophoresis. The membranes were blocked in 
a TBST buffer (137 mM NaCl, 0.1% Tween 20, 20 mM 
Tris, pH 7.6) (Cell Signaling, United States) containing 
5% of milk for 1 h, followed by incubation with the se-
lected primary antibodies at 4°С for a night. After the 
membranes were washed twice in a TBST buffer for 
5 min, the corresponding secondary antibodies (Am-
ersham, United States) were added. The membranes 
were washed three times in a TBST buffer for 10 min; 
the chemiluminescent signal was recorded by exposing 
with X-ray film (Kodak, United States) using a chemi-
luminescence kit (Perkin Elmer, United States).
RESULTS
Rabin8 decreases activity of mTORC1 
The role of Rabin8 protein in the regulation of mTORC1 
was studied using HEK293 cell line, the most widely 
used model in such experiments [11]. The cells were 
transfected with pcDNA3.1 control vector (Fig. 1, lanes 
1, 3, and 5) or Rabin8 (Fig. 1, lanes 2, 4, and 6). In the 
case of the control vector, if the medium contained 
growth factors (Fig. 1, lane 1) mTORC1 was activated, 
which was measured by the phosphorylation level of 
ribosomal protein S6 (the bottom panel). In the absence 
of growth factors (Fig. 1, lane 3), mTORC1 activity was 
partially inhibited; the subsequent short-term stimula-
tion of the cells after starvation with the medium con-
taining growth factors (Fig. 1, lane 5) resulted in the 
complete reactivation of mTORC1. A high level of Rab-
in8 expression (top panel) had no effect on the activ-
ity of mTORC1 (Fig. 1, lane 2) in the medium contain-
ing growth factors; however, it resulted in a decrease 
of mTORC1 activity in the absence of growth factors 
(Fig. 1, lane 4), and after reactivation of mTORC1 with 
the medium containing growth factors (Fig. 1, lane 6).
Inhibition of expression of Rabin8 or tuberin 
results in activation of mTORC1 
The data obtained using over-expression of Rabin8 was 
confirmed using siRNAs, synthetic short RNA duplex-RESEARCH ARTICLES
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es which initiate the targeted degradation of mRNA 
that is complementary to them. The following siRNAs 
were used as the negative and positive controls: siRNA 
without the complementary sequence in the human ge-
nomic mRNA (the control siRNA), and siRNA against 
mRNA of tuberin, the protein forming a heterodimeric 
complex with hamartin, as mentioned above. This com-
plex inhibits the activity of Rheb GTPase and, there-
fore, the activity of mTORC1. After transfection with 
control siRNA (Fig. 2, lanes 1, 4, and 7), similar to the 
transfection with control vector (see Fig. 1), the pres-
ence of growth factors in the medium (Fig. 2, lane 1) 
resulted in the activation of mTORC1. In the absence 
of growth factors (Fig. 2, lane 4), mTORC1 activity was 
inhibited. A short-term (15 min) stimulation of the cells 
grown in the medium without growth factors reacti-
vated mTORC1 (Fig. 2, lane 7). The decrease in the ex-
pression of both tuberin and Rabin8 proteins that was 
observed after transfection of siRNAs against mRNA 
of these proteins stimulated mTORC1 activity in the 
presence of growth factors (Fig. 2, lanes 2 and 3). In 
the absence of growth factors, the activity of mTORC1 
in the cells transfected with siRNA against tuberin 
mRNA marginally increased (Fig. 2, lane 5). The activi-
ty of mTORC1 remained unchanged after the transfec-
tion of siRNA against Rabin8 mRNA (Fig. 2, lane 6), in 
comparison with the transfection of the control siRNA; 
mTORC1 activity was higher than in the control after 
reactivation with the medium containing growth fac-
tors (Fig. 2, lanes 8 and 9).
Co-immunoprecipitation of Rabin8, 
Rheb, and mTOR proteins
As follows from the obtained results, Rabin8 is a nega-
tive regulator of mTORC1. We studied the possibility 
of interaction between Rabin8, Rheb, and mTOR using 
transfection in HEK293 by simultaneous transfection 
of pcDNA3.1 and pCMVTag3A control vectors (Fig. 3А, 
lane 1) or two vectors expressing Rabin8 and Myc-
Rheb fusion protein (Fig. 3А, lanes 2–4) in a medium 
with (Fig. 3A, lanes 1 and 2) or without growth factors 
(Fig. 3A, lane 3), as well as after short-term stimula-
tion of the cells grown for 24 hr without growth factors 
(Fig. 3А, lane 4). In order to study the interaction be-
tween Rabin8 and Rheb, the co-immunoprecipitation of 
cell lysates with antibodies against Rabin8 was carried 
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  Ser235/236  32 kDa
Fig. 1. Rabin8 overexpression suppresses mTORC1 activ-
ity in HEK293 cells (lanes 4, 6). The cells were transfected 
with control vector pcDNA3.1 (lanes 1, 3, 5) or with 
Rabin8 (lanes 2, 4, 6). Activity of mTORC1 was analyzed 
by levels of ribosomal protein S6 phosphorylation with 
phospho-specific antibody against S6 (Ser235/Ser236) 
in the presence of growth factors (lanes 3,4), absence of 
growth factors (lanes 3, 4), and after 15-min stimulation 
of cells grown in the growth-factor-free medium with  the 
medium containing growth factors  (lanes 5,6). The levels 
of Rabin8 and β-аctin were measured using immunoblot 
analysis with specific antibodies.
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Fig. 2. Downregulation of Rabin8 using siRNA activates 
mTORC1 activity in HEK293 cells (lanes 3,9), as well as 
downregulation of tuberin used here as a positive con-
trol (lanes 2,8). Activity of mTORC1 was analyzed in the 
same manner as in Fig. 1 in the presence of growth factors 
(lanes 1–3), in the absence of growth factors (lanes 4–7), 
and after 15-min stimulation of cells grown in the growth-
factor-free medium with the medium containing growth 
factors (lanes 7–9). The levels of Rabin8 and tuberin were 
measured using immunoblot analysis with specific antibod-
ies. Control siRNA – lanes 1,4,7.74 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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out, followed by immunoblotting with antibodies against 
Myc epitope of the Myc-Rheb fusion protein (Fig. 3B). 
It was found that the interaction of Rheb with Rabin8 
was independent of the presence of growth factors in the 
medium (Fig. 3B, lanes 2–4). Rheb was not detected af-
ter immunoprecipitation with antibodies against Rabin8 
in the control lysate without expression of Myc-Rheb 
(Fig. 3B, lane 1) or in the lysate in which non-specific 
control rabbit IgG was used for co-immunoprecipitation 
(Fig. 3B, lane 5). In order to confirm the interaction be-
tween Rabin8 and Rheb proteins, reciprocal co-immuno-
precipitation was carried out. Cell lysates were incubated 
with antibodies against Myc epitope of Myc-Rheb fusion 
protein; antibodies against mTOR and Rabin8 were used 
for the subsequent immunoblotting. As expected, Rheb 
and mTOR interacted in the presence of growth factors 
in the medium (Fig. 3B, lanes 2 and 4). Rheb and Rabin8 
interacted in the medium containing growth factors as 
well (Fig. 3B, lanes 2 and 4); however, neither interac-
tion between Rheb and Rabin8 nor between Rheb and 
mTOR was detected in the absence of growth factors 
(Fig. 3B, lane 3).
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Fig. 3. Co-immunoprecipitaion of Rabin8 and Rheb overexpressed in HEK293 cells after transfection with proper vec-
tors. The levels of Rabin8, tuberin, mTOR and β-аctin were measured using immunoblot analysis with specific antibod-
ies. (a) The expression levels of Rabin8, Myc-Rheb, and mTOR after co-transfection with control vectors pcDNA3.1 and 
pCMVTag3A (lane 1) or Rabin8 and Myc-Rheb (lanes 2–4) in the presence of growth factors (lanes 1,2), absence of 
growth factors (lane 3), and after 15-min stimulation of cells grown in media without growth factors with media contain-
ing growth factors (lane 4). (b) Co-immunoprecipitation using the lysates from  Fig. 3a with antibodies against Rabin 8 
(lanes 1–4) or control rabbit IgG (lane 5) and immunoblot analysis with antibody against Myc. The lysate from  Fig. 3a 
(lane 2) was used for the co-immunoprecipitation with control rabbit IgG antibody. (c) Co-immunoprecipitation using 
the lysates from  Fig. 3a with antibodies against Myc and immunoblot analysis with antibody against Rabin8, mTOR, and 
Myc.RESEARCH ARTICLES
 VOL. 3  № 3 (10)  2011  | ACTA NATURAE | 75
DISCUSSION
In the present study we first demonstrated that Rab-
in8 regulates phosphorylation of Ser235/Ser236 in ri-
bosomal protein S6. It has been previously shown that 
Ser235/Ser236 is phosphorylated by protein kinase 
S6K1 as a result of the activation of mTORC1, whereas 
the inhibitor of mTORC1, rapamycin, completely blocks 
phosphorylation of these residues under any conditions 
[2]. In accordance with this, the phosphorylation level of 
Ser235/Ser236 in protein S6 can be used as a conven-
ient indicator of mTORC1 kinase activity. The obtained 
data suggest that Rabin8 regulates the activity of this 
complex. However, the role of the phosphorylation of 
protein S6 in the regulation of protein synthesis has 
not been completely determined. Transgenic mice were 
generated in which all amino acid residues in protein 
S6 were replaced with nonphosphorylatable alanine 
residues; however, the level of protein synthesis in dif-
ferent cell types in these mice remained the same as in 
wild-type mice [12].
We determined the phosphorylation of Ser235/
Ser236 in protein S6 under various conditions, such 
as after cell growth in the medium containing growth 
factors (DMEM + 10% FBS), after growing the cells in 
the medium without growth factors (DMEM), and after 
short-term stimulation with growth factors (DMEM –> 
DMEM + 10% FBS) of the cells grown in the medium 
containing no growth factors. Since the regulation of 
mTORC1 is performed at several levels, the use of dif-
ferent growth conditions makes it easier to better un-
derstand the possible regulation mechanisms [13]. In all 
cases, we used DMEM medium containing amino acids, 
since the absence of amino acids results in the complete 
inhibition of mTORC1 regardless of its negative regula-
tor tuberin [14]. The absence of growth factors activates 
GAP protein tuberin, which stimulates the transition of 
Rheb GTPase from the active GTP-bound form into 
inactive GDP-bound form, resulting in the inhibition of 
mTORC1 [15, 16]. Under these conditions, any changes 
inhibiting the GAP activity of tuberin or stimulating 
the transition of Rheb GTPase into an active form will 
activate mTORC1, which was indeed observed.
We also used the short-term stimulation of the cells 
grown in a growth-factor-free medium by growth 
factors to differentiate the changes in the activity of 
mTORC1, which occur at different rates. We found that 
if cells grow in a complete medium containing growth 
factors, the decrease in Rabin8 expression stimulated 
mTORC1 activity; however, Rabin8 overexpression was 
not sufficient to inhibit this complex. In a medium with-
out growth factors, the decrease in Rabin8 expression 
was insufficient for the reactivation of the mTORC1; 
however, Rabin8 overexpression enhanced the inhibi-
tion of mTORC1. Rabin8 overexpression decreased the 
reactivation of mTORC1 resulted from the short-term 
stimulation by the medium with growth factors, while 
the decrease in Rabin8 expression stimulated reactiva-
tion. These results suggest that Rabin8 suppresses the 
activation of mTORC1 by growth factors.
We demonstrate for the first time that Rabin8 is 
bound to the major regulator of mTORC1, Rheb GT-
Pase, which is important for the understanding of the 
regulation mechanism of mTORC1 by Rabin8 protein. 
However, it is possible that Rabin8 may interact with 
other components of mTORC1 as well, since we de-
tected the catalytic subunit mTOR in complex with 
Rabin8 and Rheb after immunoprecipitation.There 
is also a possibility of mediated interaction between 
Rabin8 and Rheb via an unknown protein or tuberin/
hamartin. However, considering that both Rab8 and 
Rheb belong to the family of GTPases and partici -
pate in the regulation of primary cilia formation [9], 
we suppose that Rabin8 has an effect on the activity 
of mTORC1 via Rheb GTPase. Co-immunoprecipita-
tion experiments support this assumption, since no 
attenuation of the interaction between Rabin8 and 
Rheb proteins was detected in the growth-factor-free 
medium when using antibodies against Myc epitope 
in Myc-Rheb protein. Meanwhile, the interaction be-
tween Rheb and mTOR was abrogated, which agrees 
with previously published data [1]. No interaction be-
tween Rabin8 and Rheb proteins was detected in the 
reciprocal co-immunoprecipitation experiments for 
Rabin8, which can  account for the different affinities 
of antibodies towards these proteins.
The possibility of interaction between the Rabin8 and 
Rheb proteins suggests a novel Rheb-dependent mech-
anism of regulating the primary cilia formation, which 
is independent of the activity of mTORC1 [8]. Accord-
ing to this assumption, after interaction between Rheb 
and Rabin8, redistribution of the Rheb function from 
the regulation of mTORC1 to the regulation of primary 
cilia formation occurs. The link between the disruption 
of the ciliogenesis function and various diseases isolated 
into a separate group of ciliopathies has recently been 
established. In particular, this group includes such dis-
eases as polycystic kidney disease, the Bardet-Biedl 
syndrom, etc. [17]. The link between the disruption of 
ciliogenesis and obesity has recently been revealed [18]. 
In addition, primary cilia regulate the activity of the 
Hedgehog and Wnt signaling pathways, and disrup- signaling pathways, and disrup-  pathways, and disrup-
tion of their activity is involved in tumor development 
in various organs [19]. It should also be mentioned that 
activation of mTORC1 is observed in many types of tu- tu-
mors [20] and is required for their progression. There-  [20] and is required for their progression. There-
fore, understanding of the regulation mechanisms and 
the relationship between the mTORC1 complex and 
the processes of primary cilia formation should result in 76 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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the emergence of new approaches to the treatment of 
ciliopathies, obesity, and oncological diseases. 
This study was carried out within the framework 
of inter-institute collaboration between the Pirogov 
Russian State Medical University (Division of 
Molecular Biology and Medical Biotechnology) and the 
Fox Chase Cancer Center (Philadelphia, United States). 
The authors are grateful to O.G. Kulakova and D.I. 
Khabibullin for helpful discussions.
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